About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Massachusetts | 361 Studies

Clinical Trials MelanomaMassachusetts

Melanoma Clinical Trials in Massachusetts

Find 361 clinical trials for melanoma near Massachusetts. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Massachusetts

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 81-100 of 361 trials

TerminatedA Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaThe purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.NCT05002569·Birmingham, Alabama and 183 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

UnknownA Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in…NCT02637531·San Diego, California and 10 others

CompletedSorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By SurgeryThis randomized phase II trial is studying how well giving sorafenib together with either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that cannot…NCT00281957·Little Rock, Arkansas and 172 others

CompletedA Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaThe purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab…NCT03635983·Tucson, Arizona and 166 others

CompletedA Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaCLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily…NCT01436656·Tampa, Florida and 23 others

CompletedPanobinostat (LBH589) in Patients With Metastatic MelanomaThe purpose of this research study is to determine the safety of LBH589 as well as to find out what side effects it may cause and how effective it is against melanoma.NCT01065467·Boston, Massachusetts

WithdrawnA Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaThis research study is studying different immunotherapy regimens as a possible treatment for stage III or IV resectable melanoma.NCT04007588·Boston, Massachusetts and 1 other

CompletedBevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV MelanomaThe purpose of this research study is to determine the safety of using the study drugs bevacizumab and ipilimumab together, and the doses in combination which can be given to…NCT00790010·Boston, Massachusetts and 2 others

Active not recruitingUse of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment DiscontinuationThe goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung…NCT06146920·Boston, Massachusetts

Active not recruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple…NCT02465060·Birmingham, Alabama and 1409 others

RecruitingSafety and Tolerability Study of GIM-531 in Advanced Solid TumorsGIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy.NCT06425926·Scottsdale, Arizona and 10 others

CompletedSafety, Pharmacokinetics (PK) of AKT and MEK CombinationThis study is a Phase 1 dose-escalation open-label study to determine the recommended Phase II dose (RP2D) and regimen for the combination of the orally administered MEK inhibitor…NCT01138085·Aurora, Colorado and 9 others

CompletedIL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced MelanomaThe purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting…NCT01288963·Boston, Massachusetts

TerminatedDose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsThe purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and…NCT03114319·Tampa, Florida and 17 others

TerminatedStudy of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTo determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients…NCT04301011·Phoenix, Arizona and 10 others

CompletedA Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsThe primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced…NCT06131398·Duarte, California and 24 others

CompletedStudy of CP-675,206 in Refractory MelanomaCP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes.NCT00254579·Scottsdale, Arizona and 64 others

TerminatedCediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerThis phase I trial is studying the side effects and best dose of cediranib maleate when given together with whole brain radiation therapy in treating patients with brain…NCT00937482·Boston, Massachusetts

Active not recruitingVeliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionThis phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are…NCT01366144·Duarte, California and 16 others

TerminatedA Study of Volociximab in Metastatic MelanomaThis is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma.NCT00369395·Scottsdale, Arizona and 6 others

PreviousPage 5 of 19Next

Other Conditions in Massachusetts

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma